Mode of Action
Mode of Action
LYFNUA®▼ (gefapixant)
Prescribing Information [External link]
LYFNUA is indicated in adults for the treatment of refractory and unexplained chronic cough1
LYFNUA is available by private prescription only and is not available via the NHS
LYFNUA®▼ (gefapixant) is thought to reduce cough by targeting and inhibiting the activation of the P2X3 receptor1
Watch the video below to find out more
Always refer to the full Summary of Product Characteristics before prescribing for up to-date and complete safety considerations to help minimise the risks associated with the use of LYFNUA.
Please click here for the Summary of Product Characteristics [External link]
Stay informed about the latest on LYFNUA
Click the sign up button and consent to receive promotional emails, resources and invitations to meetings
References
- LYFNUA Summary of Product Characteristics.
Supporting documentation
LYFNUA®▼ (gefapixant)
Prescribing Information (Great Britain)
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website
